KINGSEY
FALLS, QC, May 9, 2024 /PRNewswire/ - Cascades
Inc. (TSX: CAS) reports its unaudited financial results for the
three-month period ended March 31,
2024.
Q1 2024 Highlights
- Sales of $1,109 million (compared
with $1,138 million in Q4 2023 and
$1,134 million in Q1 2023);
- Operating income of $9 million
(compared with operating loss of $(24)
million in Q4 2023 and operating loss of $(80) million in Q1 2023);
- Net loss per common share of ($0.20) (compared with ($0.57) in Q4 2023 and ($0.75) in Q1 2023);
- Adjusted earnings before interest, taxes, depreciation and
amortization (EBITDA (A)1) of $103 million (compared with $122 million in Q4 2023 and $134 million in Q1 2023);
- Adjusted net earnings (loss) per common share1 of
$0.00 (compared with adjusted net
earnings per common share1 of $0.05 in Q4 2023 and adjusted net earnings per
common share1 of $0.32 in
Q1 2023);
- Net debt1 of $2,020
million as of March 31, 2024
(compared with $1,882 million as of
December 31, 2023). Net debt to
EBITDA (A) ratio1 of 3.8x, up from 3.4x as of
December 31, 2023;
- On April 12, 2024, the
Corporation entered into a $175
million delayed draw unsecured term loan credit facility to
manage upcoming maturities;
- Total capital expenditures, net of disposals, of $41 million in Q1 2024, compared to $46 million in Q4 2023 and $137 million in Q1 2023. The Corporation's 2024
forecasted net capital expenditures of approximately $175 million is unchanged.
Mario Plourde, President and CEO,
commented: "First quarter 2024 results met expectations,
considering the context of elevated raw material prices, and
ongoing inflationary pressure on operational costs. Sequentially,
Tissue Papers executed well, with increased average selling prices
partially offsetting the impacts from higher maintenance costs and
softer seasonal volumes. Results in Containerboard decreased from
the previous quarter, as spreads remained under pressure due to
cost headwinds, most noticeably in raw materials and energy, and
lower selling prices prior to the implementation of published index
price increases effective in the second quarter. The softer results
similarly reflect costs associated with the Trenton mill, which ceased operations at the
end of January prior to its permanent closure at the end of
February. Conversely, Specialty Products had a solid quarter,
driven by favourable sequential raw material and selling prices,
and operational cost benefits reflecting efficiency and
productivity initiatives. Lower consolidated profitability levels,
higher seasonal working capital requirements and a less favourable
exchange rate during the quarter resulted in our leverage
ratio1 increasing to 3.8x from 3.4x at the end of
2023."
Discussing near-term outlook, Mr. Plourde commented,
"Consolidated second quarter results are expected to be stronger
sequentially, driven by improved performance in our Containerboard
segment as index price increases are implemented, and stable
results in the Tissue Papers and Specialty Packaging businesses. We
are continuing to advance the Bear
Island facility ramp-up. It is progressing well, and we are
pleased that the mill has achieved production levels above its
rated daily capacity on several occasions. Broadly, we are
cautiously optimistic for near-term volumes in our packaging
businesses given continued economic uncertainty, and remain focused
on profitability, efficiency and productivity initiatives and the
ramp-up of Bear Island to create value throughout
our operations."
1
|
Some information
represents non-IFRS Accounting Standards Financial measures, other
financial measures or non-IFRS Accounting Standards ratios which
are not standardized under IFRS Accounting Standards and therefore
might not be comparable to similar financial measures disclosed by
other corporations. Please refer to the "Supplemental Information
on Non-IFRS Accounting Standards Measures and Other Financial
Measures" section for a
complete reconciliation.
|
Financial Summary
Selected consolidated information
(in millions of
Canadian dollars, except amounts per common share)
(unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
|
|
|
|
Sales
|
1,109
|
1,138
|
1,134
|
As
Reported
|
|
|
|
Operating income
(loss)
|
9
|
(24)
|
(80)
|
Net loss
|
(20)
|
(57)
|
(75)
|
per common share
(basic)
|
($0.20)
|
($0.57)
|
($0.75)
|
Adjusted1
|
|
|
|
Earnings before
interest, taxes, depreciation and amortization (EBITDA
(A))
|
103
|
122
|
134
|
Net earnings
(loss)
|
—
|
5
|
33
|
per common share
(basic)
|
$—
|
$0.05
|
$0.32
|
Margin (EBITDA (A) /
Sales)
|
9.3 %
|
10.7 %
|
11.8 %
|
Segmented sales
(in millions of
Canadian dollars) (unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
556
|
561
|
561
|
Specialty
Products
|
160
|
160
|
161
|
Inter-segment
sales
|
(7)
|
(8)
|
(7)
|
|
709
|
713
|
715
|
Tissue
Papers
|
367
|
390
|
387
|
Inter-segment sales,
Corporate, Recovery and Recycling activities
|
33
|
35
|
32
|
Sales
|
1,109
|
1,138
|
1,134
|
Segmented operating income (loss)
(in millions of
Canadian dollars) (unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
(7)
|
(33)
|
38
|
Specialty
Products
|
19
|
13
|
21
|
|
|
|
|
Tissue
Papers
|
31
|
34
|
(92)
|
|
|
|
|
Corporate, Recovery and
Recycling activities
|
(34)
|
(38)
|
(47)
|
Operating income
(loss)
|
9
|
(24)
|
(80)
|
Segmented EBITDA (A)1
(in millions of
Canadian dollars) (unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
50
|
67
|
126
|
Specialty
Products
|
25
|
19
|
27
|
|
|
|
|
Tissue
Papers
|
50
|
61
|
16
|
|
|
|
|
Corporate, Recovery and
Recycling activities
|
(22)
|
(25)
|
(35)
|
EBITDA
(A)1
|
103
|
122
|
134
|
1
|
Please refer to the
"Supplemental Information on Non-IFRS Accounting Standards Measures
and Other Financial Measures" section for a complete
reconciliation.
|
Analysis of results for the
three-month period ended March 31,
2024 (compared to the same period last year)
The first quarter sales of $1,109
million decreased by $25
million compared with the same period last year. This
decrease was driven by a $64 million
impact from lower selling prices in all of our business segments.
This was partially offset by a $23
million benefit from a more favourable sales mix in the
Tissue segment, and a $16 million
benefit from higher volume, the latter of which was a net result of
a $46 million volume benefit in our
packaging businesses and a $30
million negative volume impact in our Tissue business that
reflects operational platform changes including closures completed
in the past year.
The first quarter EBITDA (A)1 totaled $103 million, a decrease of $31 million, or
23%, from the $134 million generated
in the same period last year. This decrease was largely driven by
lower selling prices, primarily in the Containerboard segment, and
higher raw material costs in our packaging businesses, the effects
of which were partially offset by stronger volumes in these
businesses. Production and freight costs were a headwind in
Containerboard but were a tailwind for the Tissue Papers business,
largely attributable to the optimization of this segment's
operational base.
The main specific items, before income taxes, that impacted our
first quarter 2024 operating income and/or net loss were:
- $28 million of impairment charges
on assets, restructuring costs and other costs related to the
closure of plants in Canada and
the USA (operating income and net
loss);
- $1 million unrealized gain on
financial instruments (operating income and net loss);
- $2 million unrealized gain on
interest rate swaps (net loss);
- $1 million foreign exchange loss
on long-term debt and financial instruments (net loss);
For the three-month period ended March 31, 2024, the
Corporation posted a net loss of $(20)
million, or ($0.20) per common
share, compared to a net loss of $(75)
million, or ($0.75) per common
share, in the same period of 2023. On an adjusted
basis1, the Corporation posted a net loss of less than a
million dollars in the first quarter of 2024, or $0.00 per common share, compared to net earnings
of $33 million, or $0.32 per common share, in the same period of
2023.
1
|
Please refer to the
"Supplemental Information on Non-IFRS Accounting Standards Measures
and Other Financial Measures" section for a complete
reconciliation.
|
Dividend on common shares and
normal course issuer bid
The Board of Directors of Cascades declared a quarterly dividend
of $0.12 per common share to be paid
on June 6, 2024 to shareholders of
record at the close of business on May 23,
2024. This dividend is an "eligible dividend" as per the
Income Tax Act (R.C.S. (1985), Canada). During the first quarter of 2024,
Cascades purchased no common shares for cancellation.
2024 First Quarter Results
Conference Call Details
Management will discuss the 2024 first quarter financial results
during a conference call today at 9:00 a.m.
ET. The call can be accessed by dialing 1-888-390-0620
(international 1-416-764-8651). The conference call, including the
investor presentation, will be broadcast live on the Cascades
website (www.cascades.com) under the "Investors" section. A replay
of the call will be available on the Cascades website and may also
be accessed by phone until June 9,
2024 by dialing 1-888-390-0541 (international
1-416-764-8677), access code 655937.
Founded in 1964, Cascades offers sustainable, innovative and
value-added packaging, hygiene and recovery solutions. The company
employs approximately 9,800 women and men across a network of
close to 70 facilities in North
America. Driven by its participative management, half a
century of experience in recycling, and continuous research and
development efforts, Cascades continues to provide innovative
products that customers have come to rely on, while contributing to
the well-being of people, communities and the entire planet.
Cascades' shares trade on the Toronto Stock Exchange under the
ticker symbol CAS. Certain statements in this release, including
statements regarding future results and performance, are
forward-looking statements based on current expectations. The
accuracy of such statements is subject to a number of risks,
uncertainties and assumptions that may cause actual results to
differ materially from those projected, including, but not limited
to, the effect of general economic conditions, decreases in demand
for the Corporation's products, increases in raw material costs,
fluctuations in selling prices and adverse changes in general
market and industry conditions and other factors.
CONSOLIDATED BALANCE SHEETS
(in millions of
Canadian dollars) (unaudited)
|
March 31,
2024
|
December 31,
2023
|
Assets
|
|
|
Current
assets
|
|
|
Cash and cash
equivalents
|
31
|
54
|
Accounts
receivable
|
469
|
453
|
Current income tax
assets
|
11
|
12
|
Inventories
|
645
|
568
|
Current portion of
financial assets
|
—
|
1
|
|
1,156
|
1,088
|
Long-term
assets
|
|
|
Investments in
associates and joint ventures
|
98
|
94
|
Property, plant and
equipment
|
2,770
|
2,808
|
Intangible assets with
finite useful life
|
51
|
55
|
Financial
assets
|
1
|
—
|
Other assets
|
83
|
78
|
Deferred income tax
assets
|
169
|
167
|
Goodwill and other
intangible assets with indefinite useful life
|
488
|
482
|
|
4,816
|
4,772
|
Liabilities and
Equity
|
|
|
Current
liabilities
|
|
|
Bank loans and
advances
|
2
|
—
|
Trade and other
payables
|
654
|
703
|
Current income tax
liabilities
|
3
|
6
|
Current portion of
Unsecured senior notes of $175 million to be refinanced
|
175
|
—
|
Current portion of
long-term debt
|
58
|
67
|
Current portion of
provisions for contingencies and charges
|
22
|
14
|
Current portion of
financial liabilities and other liabilities
|
27
|
29
|
|
941
|
819
|
Long-term
liabilities
|
|
|
Long-term
debt
|
1,816
|
1,869
|
Provisions for
contingencies and charges
|
63
|
61
|
Financial
liabilities
|
2
|
5
|
Other
liabilities
|
91
|
94
|
Deferred income tax
liabilities
|
134
|
143
|
|
3,047
|
2,991
|
Equity
|
|
|
Capital
stock
|
613
|
613
|
Contributed
surplus
|
16
|
15
|
Retained
earnings
|
1,067
|
1,096
|
Accumulated other
comprehensive income
|
31
|
15
|
Equity attributable
to Shareholders
|
1,727
|
1,739
|
Non-controlling
interests
|
42
|
42
|
Total
equity
|
1,769
|
1,781
|
|
4,816
|
4,772
|
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
|
For the 3-month
periods
ended March 31,
|
(in millions of
Canadian dollars, except per common share amounts and number of
common shares) (unaudited)
|
2024
|
2023
|
Sales
|
1,109
|
1,134
|
|
|
|
Supply chain and
logistic
|
668
|
663
|
Wages and employee
benefits expenses
|
267
|
273
|
Depreciation and
amortization
|
67
|
62
|
Maintenance and
repair
|
62
|
58
|
Other operational
costs
|
9
|
6
|
Impairment
charges
|
2
|
152
|
Other loss
(gain)
|
3
|
(2)
|
Restructuring
costs
|
23
|
1
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
1
|
Operating income
(loss)
|
9
|
(80)
|
Financing
expense
|
35
|
23
|
Share of results of
associates and joint ventures
|
(3)
|
(12)
|
Loss before income
taxes
|
(23)
|
(91)
|
Recovery of income
taxes
|
(6)
|
(24)
|
Net loss including
non-controlling interests for the period
|
(17)
|
(67)
|
Net earnings
attributable to non-controlling interests
|
3
|
8
|
Net loss
attributable to Shareholders for the period
|
(20)
|
(75)
|
Net loss per common
share
|
|
|
Basic
|
($0.20)
|
($0.75)
|
Diluted
|
($0.20)
|
($0.75)
|
Weighted average
basic number of common shares outstanding
|
100,703,177
|
100,361,627
|
Weighted average
number of diluted common shares
|
101,216,020
|
100,701,239
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(LOSS)
|
For the 3-month
periods
ended March 31,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
Net loss including
non-controlling interests for the period
|
(17)
|
(67)
|
Other comprehensive
income (loss)
|
|
|
Items that may be
reclassified subsequently to earnings
|
|
|
Translation
adjustments
|
|
|
Change in foreign
currency translation of foreign subsidiaries
|
26
|
(2)
|
Change in foreign
currency translation related to net investment hedging
activities
|
(10)
|
1
|
Cash flow
hedges
|
|
|
Change in fair value
of commodity derivative financial instruments
|
—
|
(6)
|
Recovery of income
taxes
|
1
|
1
|
|
17
|
(6)
|
Items that are not
released to earnings
|
|
|
Actuarial gain on
employee future benefits
|
7
|
1
|
Provision for income
taxes
|
(2)
|
—
|
|
5
|
1
|
Other comprehensive
income (loss)
|
22
|
(5)
|
Comprehensive income
(loss) including non-controlling interests for the
period
|
5
|
(72)
|
Comprehensive income
attributable to non-controlling interests for
the period
|
4
|
8
|
Comprehensive income
(loss) attributable to Shareholders for
the period
|
1
|
(80)
|
CONSOLIDATED STATEMENTS OF EQUITY
|
For the 3-month
period ended March 31, 2024
|
(in millions of
Canadian dollars)
(unaudited)
|
CAPITAL
STOCK
|
CONTRIBUTED
SURPLUS
|
RETAINED
EARNINGS
|
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
|
TOTAL EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS
|
NON-
CONTROLLING
INTERESTS
|
TOTAL EQUITY
|
Balance - Beginning
of period
|
613
|
15
|
1,096
|
15
|
1,739
|
42
|
1,781
|
Comprehensive income
(loss)
|
|
|
|
|
|
|
|
Net earnings
(loss)
|
—
|
—
|
(20)
|
—
|
(20)
|
3
|
(17)
|
Other comprehensive
income
|
—
|
—
|
5
|
16
|
21
|
1
|
22
|
|
—
|
—
|
(15)
|
16
|
1
|
4
|
5
|
Dividends
|
—
|
—
|
(12)
|
—
|
(12)
|
(3)
|
(15)
|
Stock options
expense
|
—
|
1
|
—
|
—
|
1
|
—
|
1
|
Acquisition of
non-controlling
interests
|
—
|
—
|
(2)
|
—
|
(2)
|
(1)
|
(3)
|
Balance - End of
period
|
613
|
16
|
1,067
|
31
|
1,727
|
42
|
1,769
|
|
For the 3-month period
ended March 31, 2023
|
(in millions of
Canadian dollars)
(unaudited)
|
CAPITAL
STOCK
|
CONTRIBUTED
SURPLUS
|
RETAINED
EARNINGS
|
ACCUMULATED OTHER
COMPREHENSIVE INCOME
|
TOTAL EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS
|
NON-CONTROLLING
INTERESTS
|
TOTAL EQUITY
|
Balance - Beginning
of period
|
611
|
14
|
1,212
|
34
|
1,871
|
57
|
1,928
|
Comprehensive income
(loss)
|
|
|
|
|
|
|
|
Net earnings
(loss)
|
—
|
—
|
(75)
|
—
|
(75)
|
8
|
(67)
|
Other comprehensive
income (loss)
|
—
|
—
|
1
|
(6)
|
(5)
|
—
|
(5)
|
|
—
|
—
|
(74)
|
(6)
|
(80)
|
8
|
(72)
|
Dividends
|
—
|
—
|
(12)
|
—
|
(12)
|
(3)
|
(15)
|
Stock options
expense
|
—
|
1
|
—
|
—
|
1
|
—
|
1
|
Balance - End of
period
|
611
|
15
|
1,126
|
28
|
1,780
|
62
|
1,842
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
For the 3-month
periods
ended March 31,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
Operating
activities
|
|
|
Net loss attributable
to Shareholders for the period
|
(20)
|
(75)
|
Adjustments
for:
|
|
|
Financing
expense
|
35
|
23
|
Depreciation and
amortization
|
67
|
62
|
Impairment
charges
|
2
|
152
|
Other loss
(gain)
|
3
|
(2)
|
Restructuring
costs
|
23
|
1
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
1
|
Recovery of income
taxes
|
(6)
|
(24)
|
Share of results of
associates and joint ventures
|
(3)
|
(12)
|
Net earnings
attributable to non-controlling interests
|
3
|
8
|
Net financing expense
paid
|
(47)
|
(44)
|
Net income taxes
paid
|
(5)
|
(2)
|
Dividends
received
|
1
|
1
|
Provisions for
contingencies and charges and other liabilities
|
(20)
|
—
|
|
32
|
89
|
Changes in non-cash
working capital components
|
(70)
|
(46)
|
|
(38)
|
43
|
Investing
activities
|
|
|
Disposals in associates
and joint ventures
|
—
|
10
|
Payments for property,
plant and equipment
|
(41)
|
(140)
|
Proceeds from disposals
of property, plant and equipment
|
—
|
3
|
Change in intangible
and other assets
|
—
|
(2)
|
|
(41)
|
(129)
|
Financing
activities
|
|
|
Bank loans and
advances
|
2
|
(1)
|
Change in credit
facilities
|
77
|
122
|
Change in credit
facilities without recourse to the Corporation
|
15
|
—
|
Payments of other
long-term debt, including lease obligations (2024 -
$20 million for the 3-month period; 2023 -
$14 million for the 3-month period)
|
(21)
|
(57)
|
Dividends paid to
non-controlling interests
|
(3)
|
(3)
|
Acquisition of
non-controlling interests
|
(3)
|
—
|
Dividends paid to the
Corporation's Shareholders
|
(12)
|
(12)
|
|
55
|
49
|
Net change in cash
and cash equivalents during the period
|
(24)
|
(37)
|
Currency translation
on cash and cash equivalents
|
1
|
(1)
|
Cash and cash
equivalents - Beginning of the period
|
54
|
102
|
Cash and cash
equivalents - End of the period
|
31
|
64
|
SEGMENTED INFORMATION
The Corporation's operations are managed in three segments:
Containerboard and Specialty Products (which constitutes the
Corporation's Packaging Products) and Tissue Papers. The accounting
policies of the reportable segments are the same as the
Corporation's accounting policies described in Note 2.
The Corporation's operating segments are reported in a manner
consistent with the internal reporting provided to the chief
operating decision-maker (CODM). The Chief Executive Officer has
authority for resource allocation and management of the
Corporation's performance and is therefore the CODM. The CODM
assesses the performance of each reportable segment based on sales
and earnings before interest, taxes, depreciation and amortization,
adjusted to exclude specific items (EBITDA (A)). The CODM
considers EBITDA (A) to be the best performance measure of the
Corporation's activities.
Sales for each segment are prepared on the same basis as those
of the Corporation. Inter-segment operations are recorded on the
same basis as sales to third parties, which are at fair market
value.
EBITDA (A) does not have a standardized meaning under IFRS
Accounting Standards; accordingly, it may not be comparable to
similarly named measures used by other companies. Investors should
not view EBITDA (A) as an alternative measure to, for example, net
earnings, or as a measure of operating results, which are IFRS
Accounting Standards measures.
Sales by country by business segment are presented in the
following table:
|
|
|
|
|
|
|
SALES TO
|
|
|
|
For the 3-month
periods ended March 31,
|
|
Canada
|
United
States
|
Other
countries
|
Total
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
Packaging
Products
|
|
|
|
|
|
|
|
|
Containerboard
|
322
|
329
|
232
|
231
|
2
|
1
|
556
|
561
|
Specialty
Products
|
60
|
56
|
100
|
104
|
—
|
1
|
160
|
161
|
Inter-segment
sales
|
(3)
|
(4)
|
(4)
|
(3)
|
—
|
—
|
(7)
|
(7)
|
|
379
|
381
|
328
|
332
|
2
|
2
|
709
|
715
|
Tissue
Papers
|
135
|
126
|
232
|
261
|
—
|
—
|
367
|
387
|
Inter-segment sale,
Corporate, Recovery and Recycling
activities
|
26
|
25
|
7
|
6
|
—
|
1
|
33
|
32
|
|
540
|
532
|
567
|
599
|
2
|
3
|
1,109
|
1,134
|
EBITDA (A) by business segment is reconciled to IFRS
Accounting Standards measure, namely operating income (loss), and
is presented in the following table:
|
For the 3-month
period ended March 31, 2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery and
Recycling
activities
|
Consolidated
|
Operating income
(loss)
|
(7)
|
19
|
31
|
(34)
|
9
|
Depreciation and
amortization
|
37
|
6
|
13
|
11
|
67
|
Impairment
charges
|
2
|
—
|
—
|
—
|
2
|
Other loss
|
3
|
—
|
—
|
—
|
3
|
Restructuring
costs
|
16
|
—
|
6
|
1
|
23
|
Unrealized gain on
derivative financial instruments
|
(1)
|
—
|
—
|
—
|
(1)
|
EBITDA
(A)
|
50
|
25
|
50
|
(22)
|
103
|
|
For the 3-month period
ended March 31, 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery and
Recycling
activities
|
Consolidated
|
Operating income
(loss)
|
38
|
21
|
(92)
|
(47)
|
(80)
|
Depreciation and
amortization
|
30
|
5
|
17
|
10
|
62
|
Impairment
charges
|
59
|
1
|
92
|
—
|
152
|
Other gain
|
—
|
—
|
(2)
|
—
|
(2)
|
Restructuring
costs
|
—
|
—
|
1
|
—
|
1
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
—
|
—
|
2
|
1
|
EBITDA
(A)
|
126
|
27
|
16
|
(35)
|
134
|
Payments for property, plant and equipment by business
segment are presented in the following table:
|
PAYMENTS FOR PROPERTY,
PLANT AND
EQUIPMENT
|
|
For the 3-month
periods
ended March 31,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
Packaging
Products
|
|
|
Containerboard
|
11
|
89
|
Specialty
Products
|
3
|
4
|
|
14
|
93
|
Tissue
Papers
|
8
|
9
|
Corporate, Recovery
and Recycling activities
|
6
|
3
|
Total
acquisitions
|
28
|
105
|
Right-of-use assets
acquisitions (non-cash)
|
(3)
|
(8)
|
|
25
|
97
|
Acquisitions for
property, plant and equipment included in "Trade and other
payables"
|
|
|
Beginning of the
period
|
45
|
106
|
End of the
period
|
(29)
|
(63)
|
Payments for
property, plant and equipment
|
41
|
140
|
Proceeds from
disposals of property, plant and equipment
|
—
|
(3)
|
Payments for
property, plant and equipment net of proceeds from
disposals
|
41
|
137
|
SUPPLEMENTAL INFORMATION ON
NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL
MEASURES
SPECIFIC ITEMS
The Corporation incurs some specific items that adversely or
positively affect its operating results. We believe it is useful
for readers to be aware of these items as they provide additional
information to measure performance, compare the Corporation's
results between periods, and assess operating results and
liquidity, notwithstanding these specific items. Management
believes these specific items are not necessarily reflective of the
Corporation's underlying business operations in measuring and
comparing its performance and analyzing future trends. Our
definition of specific items may differ from that of other
corporations and some of these items may arise in the future and
may reduce the Corporation's available cash.
They include, but are not limited to, charges for (reversals of)
impairment of assets, restructuring gains or costs, loss on
refinancing and repurchase of long-term debt, some deferred tax
asset provisions or reversals, premiums paid on repurchase of
long-term debt, gains or losses on the acquisition or sale of a
business unit, gains or losses on the share of results of
associates and joint ventures, unrealized gains or losses on
derivative financial instruments that do not qualify for hedge
accounting, unrealized gains or losses on interest rate swaps and
option fair value revaluation, foreign exchange gains or losses on
long-term debt and financial instruments, fair value revaluation
gains or losses on investments, specific items of discontinued
operations and other significant items of an unusual, non-cash or
non-recurring nature.
RECONCILIATION AND USES OF NON-IFRS ACCOUNTING STANDARDS
MEASURES AND OTHER FINANCIAL MEASURES
To provide more information for evaluating the Corporation's
performance, the financial information included in this analysis
contains certain data that are not performance measures under IFRS
Accounting Standards ("non-IFRS Accounting Standards measures"),
which are also calculated on an adjusted basis to exclude specific
items. We believe that providing certain key performance and
capital measures, as well as non-IFRS Accounting Standards
measures, is useful to both Management and investors, as they
provide additional information to measure the performance and
financial position of the Corporation. This also increases the
transparency and clarity of the financial information. The
following non-IFRS Accounting Standards measures and other
financial measures are used in our financial disclosures:
Non-IFRS Accounting Standards measures
- Adjusted earnings before interest, taxes, depreciation and
amortization or EBITDA (A): represents the operating income (as
published in Consolidated Statement of Earnings (Loss) of the
Consolidated Financial Statements) before depreciation and
amortization excluding specific items. Used to assess recurring
operating performance and the contribution of each segment on a
comparable basis.
- Adjusted net earnings: Used to assess the Corporation's
consolidated financial performance on a comparable basis.
- Adjusted cash flow: Used to assess the Corporation's capacity
to generate cash flows to meet financial obligations and/or
discretionary items such as share repurchases, dividend increases
and strategic investments.
- Free cash flow: Used to measure the excess cash the Corporation
generates by subtracting capital expenditures (excluding strategic
projects) from the EBITDA (A).
- Working capital: Used to assess the short-term liquidity of the
Corporation.
Other financial measures
- Total debt: Used to calculate all the Corporation's debt,
including long-term debt and bank loans. Often put in relation to
equity to calculate the debt-to-equity ratio.
- Net debt: Used to calculate the Corporation's total debt less
cash and cash equivalents. Often put in relation to EBITDA (A) to
calculate net debt to EBITDA (A) ratio.
Non-IFRS Accounting Standards ratios
- Net debt to EBITDA (A) ratio: Ratio used to assess the
Corporation's ability to pay its debt and evaluate financial
leverage.
- EBITDA (A) margin: Ratio used to assess operating performance
and the contribution of each segment on a comparable basis
calculated as a percentage of sales.
- Adjusted net earnings per common share: Ratio used to assess
the Corporation's consolidated financial performance on a
comparable basis.
- Net debt / Net debt + Shareholders' equity: Ratio used to
evaluate the Corporation's financial leverage and thus the risk to
Shareholders.
- Working capital as a percentage of sales: Ratio used to assess
the Corporation's operating liquidity performance.
- Adjusted cash flow per common share: Ratio used to assess the
Corporation's financial flexibility.
- Free cash flow ratio: Ratio used to measure the liquidity and
efficiency of how much more cash the Corporation generates than it
uses to run the business by subtracting capital expenditures
(excluding strategic projects) from the EBITDA (A) calculated as a
percentage of sales.
Non-IFRS Accounting Standards measures and other financial
measures are mainly derived from the consolidated financial
statements, but do not have meanings prescribed by IFRS Accounting
Standards. These measures have limitations as an analytical tool
and should not be considered on their own or as a substitute for an
analysis of our results as reported under IFRS Accounting
Standards. In addition, our definitions of non-IFRS Accounting
Standards measures and other financial measures may differ from
those of other corporations. Any such modification or reformulation
may be significant.
The CODM assesses the performance of each reportable segment
based on sales and earnings before interest, taxes, depreciation
and amortization, adjusted to exclude specific items
(EBITDA (A)1). The CODM considers EBITDA
(A)1 to be the best performance measure of the
Corporation's activities.
EBITDA (A)1 by business segment is reconciled to IFRS
Accounting Standards measure, namely operating income (loss), and
is presented in the following table:
|
Q1
2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery and
Recycling
activities
|
Consolidated
|
Operating income
(loss)
|
(7)
|
19
|
31
|
(34)
|
9
|
Depreciation and
amortization
|
37
|
6
|
13
|
11
|
67
|
Impairment
charges
|
2
|
—
|
—
|
—
|
2
|
Other loss
|
3
|
—
|
—
|
—
|
3
|
Restructuring
costs
|
16
|
—
|
6
|
1
|
23
|
Unrealized gain on
derivative financial instruments
|
(1)
|
—
|
—
|
—
|
(1)
|
EBITDA
(A)1
|
50
|
25
|
50
|
(22)
|
103
|
|
Q4 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery and
Recycling
activities
|
Consolidated
|
Operating income
(loss)
|
(33)
|
13
|
34
|
(38)
|
(24)
|
Depreciation and
amortization
|
39
|
5
|
17
|
12
|
73
|
Impairment
charges
|
43
|
1
|
4
|
—
|
48
|
Other loss
(gain)
|
18
|
(1)
|
(4)
|
—
|
13
|
Restructuring
costs
|
1
|
1
|
10
|
—
|
12
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
—
|
—
|
1
|
—
|
EBITDA
(A)1
|
67
|
19
|
61
|
(25)
|
122
|
|
Q1 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery and
Recycling
activities
|
Consolidated
|
Operating income
(loss)
|
38
|
21
|
(92)
|
(47)
|
(80)
|
Depreciation and
amortization
|
30
|
5
|
17
|
10
|
62
|
Impairment
charges
|
59
|
1
|
92
|
—
|
152
|
Other gain
|
—
|
—
|
(2)
|
—
|
(2)
|
Restructuring
costs
|
—
|
—
|
1
|
—
|
1
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
—
|
—
|
2
|
1
|
EBITDA
(A)1
|
126
|
27
|
16
|
(35)
|
134
|
1
|
Please refer to the
"Supplemental Information on Non-IFRS Accounting Standards Measures
and Other Financial Measures" section for a complete
reconciliation.
|
The following table reconciles net loss and net loss per common
share, as reported, with adjusted net earnings (loss)1
and adjusted net earnings (loss) per common share1:
(in millions of
Canadian dollars, except per common share amounts and number of
common shares) (unaudited)
|
NET EARNINGS
(LOSS)
|
|
NET EARNINGS
(LOSS)
PER COMMON
SHARE2
|
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
As
reported
|
(20)
|
(57)
|
(75)
|
|
($0.20)
|
($0.57)
|
($0.75)
|
Specific
items:
|
|
|
|
|
|
|
|
Impairment
charges
|
2
|
48
|
152
|
|
$0.01
|
$0.35
|
$1.14
|
Other loss
(gain)
|
3
|
13
|
(2)
|
|
$0.02
|
$0.10
|
($0.01)
|
Restructuring
costs
|
23
|
12
|
1
|
|
$0.18
|
$0.10
|
$0.01
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
—
|
1
|
|
($0.01)
|
—
|
—
|
Unrealized loss (gain)
on interest rate swaps
|
(2)
|
1
|
—
|
|
($0.01)
|
$0.01
|
—
|
Foreign exchange loss
(gain) on long-term debt and financial
instruments
|
1
|
1
|
—
|
|
$0.01
|
—
|
—
|
Share of results of
associates and joint ventures
|
—
|
(1)
|
(9)
|
|
—
|
($0.01)
|
($0.07)
|
Tax effect on specific
items, other tax adjustments and
attributable to non-controlling
interest2
|
(6)
|
(12)
|
(35)
|
|
—
|
$0.07
|
—
|
|
20
|
62
|
108
|
|
$0.20
|
$0.62
|
$1.07
|
Adjusted1
|
—
|
5
|
33
|
|
—
|
$0.05
|
$0.32
|
Weighted average
basic number of common shares
outstanding
|
|
|
|
|
100,703,177
|
100,685,574
|
100,361,627
|
The following table reconciles cash flow from operating
activities with EBITDA (A)1:
(in millions of
Canadian dollars) (unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
Cash flow from
operating activities
|
(38)
|
240
|
43
|
Changes in non-cash
working capital components
|
70
|
(149)
|
46
|
Net income taxes
paid
|
5
|
—
|
2
|
Net financing expense
paid
|
47
|
20
|
44
|
Provisions for
contingencies and charges and other liabilities, net of dividends
received
|
19
|
11
|
(1)
|
EBITDA
(A)1
|
103
|
122
|
134
|
The following table reconciles cash flow from operating
activities with cash flow from operating activities (excluding
changes in non-cash working capital components) and adjusted cash
flow from operating activities1. It also reconciles
adjusted cash flow from operating activities1 to
adjusted cash flow generated (used)1, which is also
calculated on a per common share basis:
(in millions of
Canadian dollars, except per common share amounts or otherwise
noted) (unaudited)
|
Q1
2024
|
Q4 2023
|
Q1 2023
|
Cash flow from
operating activities
|
(38)
|
240
|
43
|
Changes in non-cash
working capital components
|
70
|
(149)
|
46
|
Cash flow from
operating activities (excluding changes in non-cash working capital
components)
|
32
|
91
|
89
|
Restructuring costs
paid
|
14
|
12
|
1
|
Adjusted cash flow
from operating activities1
|
46
|
103
|
90
|
Payments for property,
plant and equipment
|
(41)
|
(47)
|
(140)
|
Change in intangible
and other assets
|
—
|
—
|
(2)
|
Lease obligation
payments
|
(20)
|
(15)
|
(14)
|
Proceeds from
disposals of property, plant and equipment
|
—
|
1
|
3
|
|
(15)
|
42
|
(63)
|
Dividends paid to
non-controlling interests
|
(3)
|
(3)
|
(3)
|
Dividends paid to the
Corporation's Shareholders and to non-controlling
interests
|
(12)
|
(12)
|
(12)
|
Adjusted cash flow
generated (used)1
|
(30)
|
27
|
(78)
|
Adjusted cash flow
generated (used) per common share1
(in Canadian
dollars)
|
($0.30)
|
$0.27
|
($0.78)
|
Weighted average
basic number of common shares outstanding
|
100,703,177
|
100,685,574
|
100,361,627
|
1
|
Please refer to the
"Supplemental Information on Non-IFRS Accounting Standards Measures
and Other Financial Measures" section for a complete
reconciliation.
|
2
|
Specific amounts per
common share are calculated on an after-tax basis and are net of
the portion attributable to non-controlling interests. Per share
amounts in line item ''Tax effect on specific items, other tax
adjustments and attributable to non-controlling interests'' only
include the effect of tax adjustments. Please refer to "Recovery of
income taxes" section for more details.
|
The following table reconciles total debt1 and net
debt1 with the ratio of net debt to adjusted earnings
before interest, taxes, depreciation and amortization (EBITDA
(A))1:
(in millions of
Canadian dollars) (unaudited)
|
March
31,
2024
|
December 31,
2023
|
March 31,
2023
|
Long-term
debt
|
1,816
|
1,869
|
2,044
|
Current portion of
Unsecured senior notes of $175 million to be refinanced
|
175
|
—
|
—
|
Current portion of
long-term debt
|
58
|
67
|
88
|
Bank loans and
advances
|
2
|
—
|
2
|
Total
debt1
|
2,051
|
1,936
|
2,134
|
Less: Cash and cash
equivalents
|
(31)
|
(54)
|
(64)
|
Net debt1 as reported
|
2,020
|
1,882
|
2,070
|
Last twelve months
EBITDA (A)1
|
527
|
558
|
452
|
Net debt / EBITDA
(A) ratio1
|
3.8x
|
3.4x
|
4.6x
|
1
|
Please refer to the
"Supplemental Information on Non-IFRS Accounting Standards Measures
and Other Financial Measures" section for a complete
reconciliation.
|
View original
content:https://www.prnewswire.com/news-releases/cascades-reports-results-for-the-first-quarter-of-2024-302140584.html
SOURCE Cascades Inc.